HK Stock Market Move | |3D MEDICINES (01244) Surges Over 14%; Partner SELLAS' Cancer Vaccine GPS Succeeds in Phase III AML Trial
3D MEDICINES (01244) surged over 14%. As of press time, it was up 14.23% at HK$2.85, with a turnover of HK$657,900.
3D MEDICINES (01244) surged over 14%, up 14.23% as of press time at HK$2.85, with a turnover of HK$657,900.
On the news front, on November 17, U.S. biopharmaceutical company Sellas Life Sciences announced that its cancer vaccine GPS met the primary overall survival (OS) endpoint in the Phase III REGAL trial for AML, with a 41% reduction in the risk of death; the median OS (mOS) was 24.0 months for the treatment group and 14.7 months for the control group. Affected by this, the company's stock price surged as much as 233% overnight, reaching its highest level since June 2019.
It is understood that 3D Medicines reached a collaboration with SELLAS in December 2020, obtaining exclusive development and commercialization rights for 3D189 and its heptavalent upgraded product GPS+ across all indications in Greater China. The company announced on October 29 that, if approved, 3D189 would become the world's first WT1 cancer vaccine. SELLAS stated that the company plans to meet with the U.S. Food and Drug Administration (FDA) to discuss an accelerated filing strategy.
Related Articles

China Securities Co., Ltd.: Electronics sector continues high growth; semiconductor localization expected to accelerate

HK Stock Market Move | ENN ENERGY (02688) rose nearly 4% in morning trading; Hong Kong city gas PB is at a historical low, and institutions are bullish on stronger dividend payouts.

CLSA: Raises BEKE-W (02423) target price to HK$67, reiterates "outperform" rating
China Securities Co., Ltd.: Electronics sector continues high growth; semiconductor localization expected to accelerate

HK Stock Market Move | ENN ENERGY (02688) rose nearly 4% in morning trading; Hong Kong city gas PB is at a historical low, and institutions are bullish on stronger dividend payouts.

CLSA: Raises BEKE-W (02423) target price to HK$67, reiterates "outperform" rating






